Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...

I. Platinum-based therapies induce DNA inter-strand crosslinks (ICLs), which exacerbate genomic instability and impede DNA replication. In BRCA1/2-deficient tumor cells, the repair of these DNA ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.

Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on March 19 positive topline results from the Phase 3 TALAPRO-3 study of ...

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...

A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...

Tokyo, Japan – Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a ...

Use of an RNA-based HRD signature significantly expands the fraction of patients with prostate cancer who may derive benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) compared with using ...